Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Pancreatic Neoplasms
Interventions
DRUG

NC-6004

"Study group (3 week/cycle):~NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1"

DRUG

Gemcitabine

"Study group (3 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)~Control group (4 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15"

Trial Locations (43)

104

Mackay Memorial Hospital, Taipei

106

National Taiwan University Hospital, Taipei

110

Taipei Medical University Hospital, Taipei

112

Koo Foundation Sun Yat-Sen Cancer Center, Taipei

Taipei Veterans General Hospital, Taipei

114

Tri-Service General Hospital, Taipei

235

Taipei Medical University-Shuang-Ho Hospital, Ministry of Health and Welfare, Taipei

333

Chang Gung Memorial Hospital, Linkou Branch, Taipei

404

China Medical University Hospital, Taichung

704

National Cheng Kung University Hospital, Tainan City

710

Chi Mei Hospital, Tainan City

Chi Mei Medical Center, Yongkang District

833

Chang Gung Memorial Hospital, Kaohsiung Branch, Kaohsiung City

1229

Makati Medical Center, Makati

40750

Taichung Veterans General Hospital, Taichung

61363

Chiayi Chang Gung Memorial Hospital, Chiayi City

80756

Kaohsiung Medical University Hospital, Kaohsiung City

169610

National Cancer Centre, Singapore

Unknown

Prince of Wales Hospital, Hong Kong

Queen Mary Hospital, Hong Kong

Aichi Cancer Center, Aichi

Chiba Cancer Center, Chiba

National Hospital Organization Kyushu Cancer Center, Fukuoka

Hokkaido University Hospital, Hokkaido

National Hospital Organization Osaka National Hospital, Osaka

Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka

Saitama Cancer Center, Saitama

National Hospital Organization Shikoku Cancer Center, Shikokuchūō

Shizuoka Cancer Center, Shizuoka

Center Hospital of the National Center for Global Health and Medicine, Tokyo

Kyorin university Hospital, Tokyo

National Cancer Center Hospital East, Tokyo

National Cancer Center Hospital, Tokyo

The Cancer Institute Hospital of JFCR, Tokyo

The University of Tokyo Hospital, Tokyo

Kanagawa Cancer Center, Yokohama

Hospital Sultan Ismail, Johor Bahru

Hospital Kuala Lumpur, Kuala Lumpur

443-380

Ajou University Hospital (AUH), Gyeonggi-do

135-710

Samsung Medical Center (SMC), Seoul

137-701

The Catholic University of Korea, Seoul St. Mary's Hospital (CUK SSMH), Seoul

152-703

Korea University Guro Hospital (KUGH), Seoul

50-1

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
collaborator

NanoCarrier Co., Ltd.

INDUSTRY

lead

Orient Europharma Co., Ltd.

INDUSTRY

NCT02043288 - Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer | Biotech Hunter | Biotech Hunter